(NASDAQ: GNLX) Genelux's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.04%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.57%.
Genelux's earnings in 2026 is -$32,145,000.On average, 8 Wall Street analysts forecast GNLX's earnings for 2026 to be -$34,823,076, with the lowest GNLX earnings forecast at -$36,005,950, and the highest GNLX earnings forecast at -$32,461,810. On average, 6 Wall Street analysts forecast GNLX's earnings for 2027 to be -$29,477,743, with the lowest GNLX earnings forecast at -$32,054,077, and the highest GNLX earnings forecast at -$26,345,817.
In 2028, GNLX is forecast to generate $12,568,030 in earnings, with the lowest earnings forecast at -$3,512,776 and the highest earnings forecast at $29,639,044.